Management of patients with pulmonary hypertension;Management von patienten mit pulmonaler hypertonie

Anaesthesist

Volumn 61, Issue 7, 2012, Pages 574-587

  Preckel, B ^a   Eberl, S ^a   Fraßdorf J ^a   Hollmann, M W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Drug inhalation; Infusions; Intravenous; Pulmonary vascular resistance; Vasodilator agents; Ventricular dysfunction

Indexed keywords

ILOPROST; MILRINONE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE III INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; VASODILATOR AGENT;

ARTICLE; DRUG EFFICACY; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; OXYGEN THERAPY; PULMONARY HYPERTENSION; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION;

EID: 84866346455     PISSN: 00032417     EISSN: 1432055X     Source Type: Journal    
DOI: 10.1007/s00101-012-2040-2     Document Type: Article

References (77)

1. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436
2. Kovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34:888-894
3. Williams GD, Maan HA, Ramamoorthy CH et al (2010) Perioperative complications in children with pulmonary hypertension undergoing general anesthesia with ketamine. Paediatr Anaesth 20:28-37
4. Price L, Wort S, Finney S et al (2010) Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care 14:R169
5. Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493-2537
6. Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54
7. Gabbay E, Yeow W, Playford D (2007) Pulmonary arterial hypertension (PAH) is a common cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Respir Crit Care Med 175:A713-A714
8. Humbert M, Sitbon O, Chaouat A et al (2006) Pulmonary arterial hypertension in France. Am J Respir Crit Care Med 173:1023-1030
9. Peacock AJ, Murphy NF, McMurray JJ et al (2007) An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30:104-109
10. Benza RL, Miller DP, Gomberg-Maitland Metal (2010) Predicting survival in pulmonary arterial hypertension. Circulation 122:164-172
11. Keogh A, Strange G, KotlyarE et al (2011) Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J 41:235-244
12. Badesch DB, Champion HC, Gomez Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54: S55-S66
13. Oudiz RJ (2007) Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 28:233-241
14. Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease. Eur Heart J 28:230-268
15. Chaouat A, Bugnet AS, Kadaoui N et al (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189-194
16. Lettieri CJ, Nathan SD, Barnett SD et al (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746-752
17. Reich DL, Bodian CA, Krol Met al (1999) Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. Anesth Analg 89:814-822
18. Price LC, Montani D, Jais X et al (2010) Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 35:1294-1302
19. Kaw R, Pasupuleti V, Deshpande A et al (2011) Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med 105:619-624
20. Ramakrishna G, Sprung J, Ravi BS et al (2005) Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 45:1691-1699
21. Lai HC, Lai HC, Wang KY et al (2007) Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth 99:184-190
22. Memtsoudis SG, Ma Y, Chiu YLet al (2010) Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement. Anesth Analg 111:1110-1116
23. McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation 119:2250-2294
24. Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL (2011) Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol 57:1053-1061
25. Sahara M, TakahashiT, ImaiYetal (2006) New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther 20:377-386
26. McLaughlin VV, Benza RL, Rubin LJ et al (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915-1922
27. Pritts CD, Pearl RG (2010) Anesthesia for patients with pulmonary hypertension. Curr Opin Anaesthesiol 23:411-416
28. Subramaniam K, Yared JP (2007) Management of pulmonary hypertension in the operating room. Semin CardiothoracVascAnesth 11:119-136
29. Brimioulle S, Vachiéry JL, Brichant JFet al (1997) Sympathetic modulation of hypoxic pulmonary vasoconstriction in intact dogs. Cardiovasc Res 34:384-392
30. Rex S, Missant C, Segers P, Wouters PF (2007) Thoracic epidural anesthesia impairs the hemodynamic response to acute pulmonary hypertension by deteriorating right ventricular-pulmonary arterial coupling. Crit Care Med 35:222-229
31. Missant C, Rex S, Claus P et al (2011) Thoracic epidural anaesthesia disrupts the protective mechanism of homeometricautoregulat ion during right ventricular pressure overload by cardiac sympathetic blockade: a randomised controlled animal study. Eur J Anaesthesiol 28:535-543
32. Fischer LG, Aken HV, Bürkle H (2003) Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. Anesth Analg 96:1603-1616
33. Wiedemann K, Diestelhorst C (1995) The effect of sedation on pulmonary function. Anaesthesist 44:588-593
34. Hickey PR, Hansen DD, Strafford M et al (1986) Pulmonary and systemic hemodynamic effects of nitrous oxide in infants with normal and elevated pulmonary vascular resistance. Anesthesiology 65:374-378
35. Kerbaul F, Rondelet B, Motte S et al (2004) Isoflurane and desflurane impair right ventricular-pulmonary arterial coupling in dogs. Anesthesiology 101:1357-1362
36. Lennon PF, Murray PA (1996) Attenuated hypoxic pulmonary vasoconstriction during isoflurane anesthesia is abolished by cyclooxygenase inhibition in chronically instrumented dogs. Anesthesiology 84:404-414
37. Liu R, Ueda M, Okazaki N, Ishibe Y (2001) Role of potassium channels in isoflurane- and sevoflurane-induced attenuation of hypoxic pulmonary vasoconstriction in isolated perfused rabbit lungs. Anesthesiology 95:939-946
38. Bjertnaes LJ (1977) Hypoxia-induced vasoconstriction in isolated perfused lungs exposed to injectable or inhalation anesthetics. Acta Anaesthesiol Sca nd 21:133-147
39. Fox C, Kalarickal PL, Yarborough MJ, Jin JY (2008) Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for noncardiac surgery. Curr Opin Anaesthesiol 21:467-472
40. Bogert LW, Wesseling KH, Schraa O et al (2010) Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. Anaesthesia 65:1119-1125
41. Schrijen FV, Henriquez A, Carton D et al (1989) Pulmonary vascular resistance rises with lung volume on exercise in obstructed airflow disease. Clin Physiol 9:143-150
42. Strumpher J, Jacobsohn E (2011) Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. J Cardiothorac Vasc Anesth 25:687-704
43. Thomas LJ, Griffo ZJ, Roos A (1961) Effect of negative-pressure inflation of the lung on pulmonary vascular resistance. J Appl Physiol 16:451-456
44. Inglessis I, Shin JT, Lepore JJ et al (2004) Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol 44:793-798
45. Griffiths MJD, Evans TW (2005) Inhaled nitric oxide therapy in adults. N Engl J Med 353:2683-2695
46. Gerlach H, Rossaint R, Pappert D, Falke KJ (1993) Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 23:499-502
47. Hakim TS (1994) Flow-induced release of EDRF in the pulmonary vasculature: site of release and action. Am J Physiol Heart Circ Physiol 267:H363-369
48. Pagnamenta A, Fesler P, Vandinivit A et al (2003) Pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med 31:1140-1146
49. Missant C, RexS, Segers P, Wouters PF (2007) Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 35:707-715
50. Russ MA, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock improvement with levosimendan. Crit Care Med 37:3017-3023
51. Papp Z, Edes I, Fruhwald S et al (2011) Levosimendan: molecular mechanisms and clinical implications. Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. DOI 10.1016/j.ijcard.2011.07.022
52. Kleber FX, Bollmann T, Borst MM et al (2009) Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 49:109-115
53. Buckley MS, Feldman JP (2007) Nebulized milrinone use in a pulmonary hypertensive crisis. Pharmacotherapy 27:1763-1766
54. Wang H, Gong M, Zhou B, Dai A (2009) Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 26:462-468
55. Lamarche Y, Malo O, Thorin E et al (2005) Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 130:83-92
56. Sablotzki A, Starzmann W, Scheubel R et al (2005) Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 52:1076-1082
57. Lamarche Y, Perrault LP, Maltais S et al (2007) Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg 31:1081-1087
58. Haraldsson A, Kieler-Jensen N, Ricksten SE (2001) The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 93:1439-1445
59. Buckley MS, Staib RL, Wicks LM, Feldman JP (2010) Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Drug Healthc Patient Saf 2:151-161
60. Corbin J, Rannels S, Neal D et al (2003) Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 19:747-752
61. Andersen A, Nielsen JM, Peters CD et al (2008) Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 10:1158-1165
62. Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248
63. Botha P, Parry G, DarkJH, MacGowan GA (2009) Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant 28:676-682
64. Buckley MS, Wicks LM, Staib RL et al (2011) Pharmacokinetic evaluation of ambrisentan. Expert Opin Drug Metab Toxicol 7:371-380
65. Oudiz RJ, Farber HW (2009) Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 157:625-635
66. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension. Circulation 106:1477-1482
67. Opitz CFWenselR, Winkler Jetal (2005) Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26:1895-1902
68. Hoeper MM, Schwarze M, Ehlerding S et al (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prosta - cyclin analogue. N Engl J Med 342:1866-1870
69. Winterhalter M, Simon A, Fischer S et al (2008) Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 22:406-413
70. Theodoraki K, Rellia P, Thanopoulos A et al (2002) Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 49: 963-967
71. Baysal A, Bilsel S, Bulbul OG et al (2006) Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgery. Heart Surg Forum 9:536-542
72. Rex S, Schaelte G, Metzelder S et al (2008) Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand 52:65-72
73. Schroeder RA, Wood GL, Plotkin JS, Kuo PC (2000) Intraoperative use of inhaled PGI2 for acute pulmonary hypertension and right ventricular failure. Anaesth Analg 91:291-295
74. Fraisse A, ButrousG, Taylor Metal (2011) Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 37:502-509
75. Vachiery JL, Huez S, Gillies H et al (2011) Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 71:289-292
76. Lee JE, Hillier SC, Knoderer CA (2008) Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 23:329-334
77. Namachivayam P, Theilen U, Butt WW et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042-1047